Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20411084 | 1.00 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL20399351 | 1.00 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL20399624 | 0.87 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21619472 | 0.65 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL20411047 | 0.64 | SLC6A2 (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15974137 | 0.64 | CCR2 (0.36) | — | |
| SCHEMBL20411146 | 0.64 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26305272 | 0.63 | — | — | |
| SCHEMBL24536243 | 0.63 | NR1I2 (0.31) | — | |
| SCHEMBL21078059 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571198-B1 | BICYCLIC AMINES AS JAK KINASE INHIBITORS | LEO PHARMA AS (DK) | 2023-02-01 | — | — | EP | disclosed |
| US-10851116-B2 | Bicyclic amines as novel JAK kinase inhibitors | LEO PHARMA A/S (DK) | 2020-12-01 | — | — | US | disclosed |
| US-10851116-B2 | Bicyclic amines as novel JAK kinase inhibitors | LEO PHARMA A/S (DK) | 2020-12-01 | — | — | US | disclosed |
| WO-2018134352-A1 | BICYCLIC AMINES AS NOVEL JAK KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134352-A1 | BICYCLIC AMINES AS NOVEL JAK KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851116-B2 | Bicyclic amines as novel JAK kinase inhibitors | JAK1, JAK2, JAK3 | SLC6A2 3673/4885SLC6A4 3886/4885SLC6A3 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.